Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Bo Fu, Yan Peng, Shan Zhang, Yan Lü, Pan Li, Wenqiang Tang, Shen Chen, Shuangfeng Chen, Anqi Zhang, Wei LiuDisease 2018 · DOI

TL;DR

This study investigates cell-free circulating methylated SEPT9 (mSEPT9) in blood as a noninvasive biomarker for colorectal cancer (CRC). The findings suggest mSEPT9 is a promising tool for diagnosing CRC, assessing treatment effectiveness, and monitoring for recurrence, potentially improving patient outcomes.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a significant global health burden, and early detection is crucial for improving survival rates. Current screening methods like fecal occult blood tests (FOBT) have limited sensitivity, while colonoscopy, though effective, is invasive and carries risks. Furthermore, accurately monitoring treatment efficacy and detecting recurrence after surgery remains a challenge. Existing methods like CT scans and serum CEA levels have limitations in sensitivity and specificity for detecting small lesions or residual disease. This paper aims to address these gaps by evaluating mSEPT9, a methylated gene fragment found in cell-free DNA, as a less invasive and potentially more accurate biomarker for CRC diagnosis, treatment monitoring, and recurrence detection.

Methods

The researchers utilized a real-time PCR-based assay (Epi proColon 2.0 kit) to detect methylated SEPT9 (mSEPT9) in plasma samples. They employed two different algorithms for interpreting the results: a "2/3 algorithm" (higher specificity) and a "1/3 algorithm" (higher sensitivity). Clinicopathological data from patients were collected and analyzed in conjunction with mSEPT9 status. Statistical analyses included chi-square tests, Fisher exact tests, and kappa tests to assess agreement and correlations. Receiver operating characteristic (ROC) curves were generated to evaluate diagnostic performance, with Area Under the Curve (AUC) used as a metric.

Datasets

The study enrolled a total of 558 subjects, categorized as follows:

  • Colorectal Cancer (CRC): 98 patients
  • Adenoma: 101 patients
  • Noncolorectal Cancers: 76 patients (including gastric, breast, and other cancers)
  • Inflammation: 30 patients
  • No Evidence of Disease (NED) / Healthy Controls: 253 subjects

Additionally, a subset of 19 CRC patients who underwent curatively intended surgery were followed for therapeutic efficacy assessment, and 16 patients were monitored for recurrence.

Key Insights and Ideas

  • SEPT9 Methylation as a CRC Signal: The core idea is that specific methylation patterns in the SEPT9 gene, detectable in circulating cell-free DNA, are associated with the presence of CRC. This epigenetic change acts as a molecular signature of the cancer.
  • Beyond Diagnosis: Monitoring Potential: The study goes beyond simple diagnosis, exploring mSEPT9's utility in the entire patient journey – from assessing if surgery was successful to predicting if the cancer might return.
  • Algorithm Choice Matters: The choice between a high-specificity (2/3) and high-sensitivity (1/3) algorithm for mSEPT9 detection impacts its performance characteristics, suggesting different algorithms might be suited for different clinical applications (e.g., screening vs. confirmation).
  • Gastric Cancer Link: The surprisingly high mSEPT9 positivity in gastric cancer patients hints at shared molecular pathways with CRC, suggesting mSEPT9 might have broader applications in gastrointestinal oncology.
  • Post-Surgery Sentinel: Persistent mSEPT9 positivity after surgery acts as a strong warning sign for impending recurrence, potentially offering a crucial lead time for intervention.

Key Results

  • Diagnostic Value for CRC: Using the 2/3 algorithm, plasma mSEPT9 demonstrated a sensitivity of 61.22% and a specificity of 93.7% for CRC diagnosis. The AUC for CRC detection was 0.802.
  • Correlation with CRC Characteristics: mSEPT9 positivity was significantly correlated with larger tumor size (>5 cm), higher histological grade (3 and 4), and ulcerative tumor morphology.
  • Gastric Cancer Association: A high positive rate of 70% was observed in gastric cancer patients.
  • Therapeutic Efficacy: In patients undergoing curatively intended surgery, a conversion from preoperative positive mSEPT9 to postoperative negative mSEPT9 reflected successful treatment.
  • Recurrence Prediction: Persistent postoperative mSEPT9 positivity (within 7-14 days) showed 100% sensitivity in predicting impending recurrences or metastases within one year.
  • Monitoring Agreement: Postoperative mSEPT9 status during follow-up showed good consistency (kappa = 0.818) with CRC recurrence or metastases detection.
  • Adenoma Inconclusiveness: mSEPT9 showed a low positive rate in adenoma patients, suggesting it's not a reliable biomarker for detecting precancerous lesions.

Limitations and Future Work

  • Qualitative vs. Quantitative: The study primarily used qualitative detection, and further research could explore quantitative measurements for more refined insights.
  • Sample Size and Single Center: The study was conducted at a single hospital, and the authors acknowledge the need for larger, multi-center studies to confirm these findings and elucidate their full clinical utility.
  • Negative mSEPT9 in Recurrence: One case of lung metastasis with negative mSEPT9 was noted, highlighting the need to investigate mSEPT9's performance in cases where preoperative status is negative.
  • Lead Time for Recurrence: While postoperative mSEPT9 showed promise in predicting recurrence, further studies are needed to determine if it can provide clinically relevant lead times compared to conventional methods.
  • Gastric Cancer Specificity: The high positivity in gastric cancer warrants further investigation with larger cohorts to confirm its diagnostic value, particularly for specific subtypes like gastric cardia cancer.

Summary updated

Abstract

Identification of early-stage tumor and monitoring therapeutic efficacy and recurrence or metastasis of colorectal cancer (CRC) are urgently warranted for improving the outcome of CRC patients and reducing the disease-related mortality. In this study, we evaluated the diagnostic value of cell-free circulating methylated SEPT9 (mSEPT9) for CRC and beyond CRC and examined the potentiality of mSEPT9 in assessing therapeutic efficacy and monitoring recurrence of CRC. Our results confirmed the favorable diagnostic value of plasma mSEPT9 for CRC, with a sensitivity of 61.22% (95% confidence interval (CI): 51.33%-70.27%) and specificity of 93.7% (95% CI: 91.09%-95.57%) using 2/3 algorithm. The positive rate of mSEPT9 in CRC was correlated with tumor size, histological grade, and general histological type (<i>P</i> < 0.05). Beyond CRC, gastric cancer patients also presented a high positive rate of plasma mSEPT9 (70%). The conversions between preoperative and postoperative plasma mSEPT9 reflected the therapeutic efficacy of curatively intended surgery for CRC patients. The persistent positivity of plasma mSEPT9 after surgery (within 7-14 days) was highly associated with impending recurrences or metastases (within one year), with a sensitivity of 100%. Postoperative mSEPT9 status during follow-up also provided valuable indication for CRC recurrence or metastases, with a good consistency (kappa = 0.818, <i>P</i> = 0.001). Our results verified the reliability of plasma mSEPT9 as a biomarker for noninvasive diagnosis of CRC. More significantly, we revealed its valuable role in appraising CRC therapeutic efficacy and monitoring CRC recurrences or metastases. Further studies with larger sample sizes are needed to verify and elucidate the clinical utility of the promising findings.
BibTeX
@inproceedings{fu2018cell,
  author = {Bo Fu and Yan Peng and Shan Zhang and Yan Lü and Pan Li and Wenqiang Tang and Shen Chen and Shuangfeng Chen and Anqi Zhang and Wei Liu},
  title = {{Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer}},
  booktitle = {Disease},
  year = {2018},
  doi = {10.1155/2018/6437104},
}
Figure